In this session we will find out when, why and how can a collaborative corporate-entrepreneurship partnership deliver value? Our speakers will share their experience of collaborations and we will also hear about what it takes to develop a culture that encourages new ideas and provides support.
Shaun Grady is Vice-President Business Development Operations, leading AstraZeneca’s transaction execution, due diligence and Alliance and Integration Management function.
Robert Tansley has been Investment Director for Life Sciences at Cambridge Innovation Capital since 2014. Cambridge Innovation Capital combines a strong relationship with the University of Cambridge with deep financial and industry links aiming to invest its initial capital of £50 million in Cambridge companies.
Anna Williamson is a Senior Manager in the Business Development Department at Genentech. Anna’s responsibilities include sourcing, evaluating and in-licensing research technologies and therapeutic products.
Sir Gregory Winter CBE is Master of Trinity College Cambridge. He is a scientist, inventor and entrepreneur. Sir Gregory founded several successful start-up companies, including Cambridge Antibody Technology in 1990 (acquired by Astra Zeneca in 2006), Domantis in 2000 (acquired by GSK in 2006) and Bicycle Therapeutics in 2010, which is developing a peptide product for the treatment of cancer. He is a Fellow of the Royal Society and in 2004 was knighted for his services to Molecular Biology.
You can follow @CJBS_EC on Twitter.
